Acumen Pharmaceuticals (ABOS)
(Real Time Quote from BATS)
$3.34 USD
-0.20 (-5.65%)
Updated Jul 24, 2024 12:22 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABOS 3.34 -0.20(-5.65%)
Will ABOS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABOS
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
ABOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Other News for ABOS
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Buy Rating on Acumen Pharmaceuticals: Promising Alzheimer’s Treatment and Superior Safety Profile
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Buy Rating Justified: Acumen Pharmaceuticals’ Promising Position in Alzheimer’s Treatment Market
Acumen Pharmaceuticals’ Sabirnetug: A Novel Approach in Alzheimer’s Disease Treatment Warrants a Buy Rating